Chiron Corporation

Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Liya Chen

Rajinder Paul Singh

Manoj C Desai

Xiaodong Lin

Verena D Huebner

Liang Wang

Beata Krywult

Ian James

Thayalan Navaratnam

Rob Trainor

Jennifer C Moore

Dooseop Kim

Sander G Mills

Malcolm MacCoss

Amjad Ali

Dong-Ming Shen

Jeffrey John Hale

Peter J Sinclair

Charles G Caldwell

Christopher L Lynch

Kevin Tyler Chapman

Christopher Francis Thompson

Cameron James Smith

Ramzi Farah Sweis

Julianne A Hunt

Gayle E Taylor

Nazia Quraishi

Florida Kallashi

Amy Gentry

Jennifer Kowalchick

Yuan Cheng, Legal Representative

Jennifer E Kowalchick

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

CETP inhibitors

Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

Estrogen receptor modulators

Pyrrolidine compounds of Formula (I), (wherein R, R, R, R, R, R, R, Rand Rare defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described 

Pyrrolidine modulators of CCR5 chemokine receptor activity

Isoxazole estrogen receptor agonist and antagonist compounds having unexpected and surprising activity in modulating estrogen receptor activity are described. In addition, methods and compositions for treating or preventing estrogen receptor-mediated disorders are disclosed. The compounds, methods, and compositions of the invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.

Growing community of inventors

East Brunswick, NJ, United States of America

Liya Chen